Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 4/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 5/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4982245 | 0.92 | AOC3 (0.36) | AOC3RAB9APOLBMAPT | |
| SCHEMBL4990573 | 0.89 | SCD (0.39) | AOC3KMT2ARAB9APOLBMAPT | |
| SCHEMBL4982416 | 0.88 | AOC3 (0.35) | AOC3RAB9APOLBMAPT | |
| SCHEMBL4864961 | 0.88 | SCD (0.42) | AOC3RAB9APOLBMAPTRXFP1 | |
| SCHEMBL4986159 | 0.88 | AOC3 (0.37) | AOC3RXFP1 | |
| SCHEMBL4875737 | 0.87 | SCD (0.40) | AOC3RAB9APOLBMAPTRXFP1 | |
| SCHEMBL4985433 | 0.87 | AOC3 (0.39) | AOC3KMT2ARAB9APOLBMAPT | |
| SCHEMBL4989625 | 0.87 | AOC3 (0.34) | AOC3RAB9APOLBMAPT | |
| SCHEMBL4992580 | 0.87 | TBK1 (0.34) | AOC3RAB9APOLBMAPT | |
| SCHEMBL4986016 | 0.86 | AOC3 (0.36) | AOC3RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442715-B2 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2008-10-28 | — | — | US | disclosed |
| US-20060276521-A1 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276521-A1 | Thiazole derivatives | VCAM1, ICAM1, TXNL1 | AOC3 782/4885KMT2A 4395/4885RAB9A 1860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.